An Educational Module for Adolescents on Cannabis Following its Legalization

Recreational use of cannabis has been recently legalized in Vermont. One year prior to its legalization, 42% of high school students in Washington County reported at least one-time use of cannabis. An educational module for adolescents was developed to address the increasing potency of cannabis and health risks associated with its use.https://scholarworks.uvm.edu/fmclerk/1490/thumbnail.jp

Explaining Hospital Length of Stay of Patients Admitted with Seasonal Influenza Infection

The annual occurrence of seasonal influenza virus poses a significant health burden. Certain populations are at higher risk for influenza infection, such as cigarette smokers, the elderly, and patients with cardiopulmonary disorders. Monitoring the length of time that patients are hospitalized with influenza is of clinical importance. The objectives of this study were to identify characteristics of patients hospitalized with influenza and to determine whether smoking correlates to extended LOS (length of stay in hospital). It was hypothesized that smoking and COPD (Chronic Obstructive Pulmonary Disease) would most significantly explain prolonged LOS. Information was collected from a cohort of adult patients admitted to hospital with influenza during the 2012- 2013 season. Both univariate and multivariate analyses were performed to compare variables with LOS as an outcome. Among 54 patients, the median age was 73.5 and the median Body Mass Index was 26.1 kg/m2. Exactly two-thirds were smokers and just under one-third was diagnosed with COPD. Univariate statistical analyses determined that patients with COPD, diabetes, and more than one comorbid condition had significantly increased LOS (p = 0.0129*, 0.0191*, 0.0046*; respectively). A generalized linear model was generated (n = 50), revealing that patients with COPD and more than one comorbid condition significantly correlated to prolonged LOS (p = 0.0266* and 0.0079*, respectively). Smoking status was not a significan indicator for lengthier LOS in either set of analyses. Promoting the use of vaccination for individuals with COPD and extensive comorbid conditions is imperative

Eliminating Barriers: Connecting Seniors to Services in Chittenden County

Introduction. Physical activity programs for older adults help to improve physical, social, and emotional health and reduce impairments in activities of daily living1. In Chittenden county, less than 1⁄3 of older adults participate in programs, while 48% report that they would like to exercise more. Our aim was to identify barriers to participation in physical activity programs by older adults in Chittenden county, such as accessibility, transportation, health, affordability, and social isolation, and to identify strategies to overcome these barriers. Methods. 144 paper and electronic surveys were administered in Chittenden County, Vermont to assess use of group programs among older adults aged ≥ 50 years including transportation, motivation, preferences, advertisement, and barriers to access. A focus group explored aspects of ideal group activities for seniors. Results. 87.9% of respondents were active for two or more hours each week, while 46.5% had participated in group programming in the past 6 months. Group par- ticipation was significantly higher among physically active respondents (p=0.020). Motivators for participation in group activity included health benefits, social aspects, and physical activity, while the most cited barrier to attendance was timing conflicts. Respondents received information about programming via word of mouth, email, and online resources. Discussion. Overall, our findings indicate that the majority of respondents are highly active, however, they frequently experience barriers that prevent them from participating in group programming. We recommend offering flexible scheduling, advertising programming via word of mouth and email, and emphasizing program health benefits.https://scholarworks.uvm.edu/comphp_gallery/1260/thumbnail.jp

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes

CODA - A Mobile Application for Medical Discharge

CODA is a mobile application which is designed to assist with medical discharge by changing the way users organize the information their medical information. Hospital discharge is not just the moment a patient leaves the hospital, but also the patient\u27s efforts to manage their conditions outside of the hospital as well as provider\u27s efforts to prepare for discharge while a patient is in the hospital. Poor discharge can lead to readmission to the hospital, increased health care costs and other poor outcomes. In this presentation the features of CODA will be detailed along with current and futures efforts

LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients

Background: Lysil oxidase like enzyme-2 (LOXL-2) and TNC-C play important roles in organ fibrosis. We assessed circulating LOXL-2 and TNC-C levels and their relationship to fibrosis severity in HIV- and/or HCV-infected individuals. Methods: Healthy controls (n = 22), HIV mono- (n = 15), HCV mono- (n = 52) and HCV/HIV-co-infected (n = 92) subjects were included. Results: LOXL-2 and TNC-C levels were significantly higher in HCV mono- and HCV/HIV-co-infected individuals with F0 compared to healthy controls. In addition, in HCV/HIV-co-infected individuals, LOXL-2 levels were higher in intermediate fibrosis compared to no/mild fibrosis. Conclusion: In HCV/HIV-co-infected study participants, both LOXL-2 and TNC-C were significantly higher in intermediate fibrosis compared to no/mild fibrosis, but did not further increase with advanced fibrosis. Furthermore, both markers were elevated among HCV/HIV-positive individuals with mild/no fibrosis

Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.

BackgroundCoinfection with human immunodeficiency virus (HIV) accelerates hepatitis C virus (HCV)-related liver fibrosis. Macrophages are triggered during both viral infections and are critical in liver inflammation/fibrogenesis. Liver fibrosis strongly associates with serum soluble CD163 (sCD163, a macrophage activation marker); comprehensive evaluation in HIV/HCV coinfection is lacking.MethodsWe retrospectively analyzed sCD163 (enzyme-linked immunosorbent assay) and hepatic CD163 (immunofluorescent CD163/CD68 costaining) in patients infected with HIV/HCV, HCV, or HIV, pre- and post-antiviral therapy.ResultssCD163 was significantly higher in HIV/HCV compared to either monoinfection, and decreased following successful antiviral therapy, although did not fully normalize. In HIV/HCV, sCD163 was associated with necroinflammation, Ishak fibrosis scores, and noninvasive fibrosis scores. We observed a novel trend whereby sCD163 levels progressively increase with increasing Ishak fibrosis score, peaking at stage 4, above which levels plateaued. Periportal CD163+ macrophage frequency was also higher with increasing fibrosis score. When stratified by fibrosis stage, sCD163 levels were higher in HIV/HCV than HCV but only in individuals with mild to moderate fibrosis.ConclusionsIn HIV/HCV, increasing sCD163 levels accompanied periportal CD163+ macrophage enrichment in mild to moderate fibrosis, but not in established cirrhosis, suggesting that sCD163 is a dynamic biomarker of fibrogenesis rather than accumulated fibrosis. Our findings implicate HIV-related macrophage activation in accelerated fibrosis progression in HIV/HCV coinfection